Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 3 years of age or older~* Patients must be planning to undergo standard of care treatment with surgery and radiation therapy.~* Patients must have malignant glioma or recurrent ependymoma~* Tumor must be accessible for injection and must not be located in the brainstem or deep midbrain~* Performance Score: Karnofsky ≥60% if \>10y/o, Lansky ≥60 if ≤10y/o~* Bone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral absolute neutrophil count ≥ 1000/µl, platelet count ≥ 100,000/µl (transfusion independent) and hemoglobin ≥ 8.0 gm/dL~* Renal Function: Patients must have serum creatinine ≤ 1.5 times upper limit of institutional normal for age and/or GFR ≥ 70 mL/min/1.73 m2.~* Hepatic Function: Bilirubin ≤ 1.5 times institutional normal; SGPT (ALT) \< 3 times institutional normal~* Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked prior to enrollment and clinically significant abnormalities corrected prior to surgery/AdV-tk injection~* Patients with seizure disorder may be enrolled if well controlled~* Signed informed consent according to institutional guidelines must be obtained~Exclusion Criteria:~* Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection~* Patients on immunosuppressive drugs (with exception of corticosteroid)~* Known history of HIV or underlying immunodeficiency~* Patients with acute infections (viral, bacterial or fungal infections requiring therapy)~* Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy~* Other serious co-morbid illness or compromised organ function~* No other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from study entry until tumor progression)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- AdV-tk (Type: EXPERIMENTAL): AdV-tk + valacyclovir in combination with standard of care radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).